[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antidepressants\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antidepressants":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100577334","early-phase-1-deprescription-of-antidepressants-in-primary-care-dapricare-100577334",false,"NCT06796946","Deprescription of Antidepressants in Primary Care (DAPriCare)","Intervention for Antidepressant Deprescription in Primary Care: a Randomized Community Clinical Trial","DAPriCare","Inclusion Criteria:\n\n* be of legal age (≥18 years),\n* have received at least one antidepressant prescription in the year before the start of the study,\n* and have the physical capacity to go to the health center and the mental capacity to give informed consent\n\nExclusion Criteria:\n\n* minors,\n* have changed health centers,\n* have physical or mental disabilities (including advanced dementia, severe cognitive deficit, advanced Alzheimer's disease, and disability \\>70%), or,\n* are hospitalized at the time of selection",true,"ALL","18 Years",{"count":21,"type":22},325,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","Introduction The consumption of antidepressants has increased considerably worldwide, including in Spain. Despite their effectiveness in cases of moderate to severe depression, their long-term use in mild cases is questioned. This study aims to evaluate the effectiveness of a deprescribing intervention in primary care, to reduce the unnecessary consumption of these drugs and improve patients' quality of life.\n\nMaterial and Methods A community-based clinical trial will be carried out before and after in an adult population of residents of an urban area of Cadiz (Spain) who have been prescribed antidepressants in the last year. Participants will be randomly selected and followed up for a predetermined period after consensus.\n\nThe intervention will consist of a comprehensive evaluation of antidepressant treatment by a team of health professionals. Factors such as indication, dose, and response to treatment will be evaluated, and the Hamilton scale for anxiety and the Beck Inventory for depression will be used. In those cases where it is considered appropriate, a gradual reduction or suspension of the drug will be proposed, always under medical supervision.\n\nConclusions This research will contribute to generating scientific evidence on the safety and efficacy of deprescribing in primary care, promoting a more rational use of antidepressants, and improving the quality of life of patients. The results obtained could have important implications for clinical practice and for the development of clinical practice guidelines.",[28,29],"Deprescription","Antidepressants",[31,32,33,34,35,36],"Deprescribing","antidepressants","primary care","clinical trials","mental health","adverse effects","NOT_YET_RECRUITING","2026-04-28",{"date":40,"type":41},"2026-05-04","ACTUAL",{"date":43,"type":22},"2026-06",{"date":45,"type":22},"2027-03",{"name":47,"class":48},"University of Huelva","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100542028","precision-psychiatry-for-depression-immune-response-and-affective-symptoms-as-predictors-of-response-to-antidepressants-100542028","NCT06337539","Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants","LYMPHODEP","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Clinical diagnosis of major depression according to DSM-5 criteria made by a psychiatrist applying the Structured Clinical Interview for DSM-5 (SCID-5).\n* Eligible for receiving antidepressant treatment for major depression.\n\nExclusion Criteria:\n\n* Who have received antidepressant, antipsychotic or euthymizer treatments in the 6 weeks prior to inclusion in the study.\n* Who present concurrent psychotic symptoms.\n* Who present disorders due to alcohol or drug use, with active consumption during the last 3 months.\n* Pregnant women.\n* Who have serious or unstable medical disorders, Addison's or Cushing's disease, systemic inflammatory or autoimmune diseases, or primary or secondary immunodeficiencies.","65 Years",{"count":59,"type":22},50,"OBSERVATIONAL","Objectives: To identify in patients with major depression different peripheral markers of neuroinflammation in relation to affective symptoms (anxiety, depression, irritability), fatigue and cognitive symptoms; and its relationship with the response to antidepressant treatment with selective serotonin reuptake inhibitors (SSRIs).\n\nMethodology: This is a prospective observational cohort study in patients with major depression naturally subjected to treatment with SSRIs. For this, 30 patients with major depression attended in the Outpatient Psychiatry Consultations will be selected. All of them will be evaluated at baseline and after 3 months of treatment, collecting demographic and clinical variables, Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) psychiatric diagnoses, psychopathological scales and immunological and biochemical variables. The correlation between immunological markers and affective and cognitive symptoms at baseline, as well as their variation with treatment, will be analyzed. A group of 20 healthy subjects will be used as a control group.\n\nSubsequently, a bivariate comparative analysis will be carried out, where the statistically significant or marginally significant variables associated with psychopathological variables will be used to build a multivariate binary logistic regression model.",[63,64,29,65],"Depression","Inflammation","Immunity",[67,63,64,65],"Selective serotonin reuptake inhibitors","2024-03-22",{"date":70,"type":41},"2024-03-29",{"date":72,"type":22},"2024-04-01",{"date":74,"type":22},"2027-07-31",{"name":76,"class":48},"Germans Trias i Pujol Hospital"]